Anixa Biosciences, Inc. (FRA:CY71)

Market Cap	95.65M
Revenue (ttm)	n/a
Net Income (ttm)	-9.72M
Shares Out	n/a
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	2,225
Open	2.640
Previous Close	2.660
Day's Range	2.640 - 2.700
52-Week Range	2.040 - 5.000
Beta	n/a
RSI	52.92
Earnings Date	Jan 9, 2026

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company’s vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the develo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1982
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CY71

Financial Performance

Financial numbers in USD